Daily Stock Analysis, FPRX, Five Prime Therapeutics Inc, priceseries

Five Prime Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
11.52
Close
11.50
High
11.62
Low
11.13
Previous Close
11.62
Daily Price Gain
-0.12
YTD High
11.90
YTD High Date
Feb 5, 2019
YTD Low
8.60
YTD Low Date
Jan 4, 2019
YTD Price Change
2.14
YTD Gain
22.86%
52 Week High
22.75
52 Week High Date
Feb 28, 2018
52 Week Low
7.84
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-7.25
52 Week Gain
-38.67%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 25. 2017
35.83
Oct 4. 2017
37.91
7 Trading Days
5.81%
Link
LONG
Oct 10. 2017
39.13
Oct 25. 2017
43.88
11 Trading Days
12.15%
Link
LONG
Sep 12. 2018
14.38
Sep 13. 2018
15.19
1 Trading Days
5.63%
Link
Company Information
Stock Symbol
FPRX
Exchange
NasdaqGS
Company URL
http://www.fiveprime.com
Company Phone
415-365-5600
CEO
Lewis T. Williams
Headquarters
California
Business Address
TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001175505
About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company, and UCB Pharma S.A.; and license agreement with INBRX 110 LP, Galaxy Biotech, LLC, BioWa, Inc., and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.